Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6WJH

Crystal structure of MAGE-A11 bound to the PCF11 degron

Summary for 6WJH
Entry DOI10.2210/pdb6wjh/pdb
DescriptorFusion protein of PCF11 and MAGE-A11 (2 entities in total)
Functional Keywordsmage-a11, pcf 11, ubiquitin ligase, protein complex, ligase
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains4
Total formula weight111203.29
Authors
Miller, D.J.,Huang, X. (deposition date: 2020-04-13, release date: 2020-10-14, Last modification date: 2023-10-18)
Primary citationYang, S.W.,Huang, X.,Lin, W.,Min, J.,Miller, D.J.,Mayasundari, A.,Rodrigues, P.,Griffith, E.C.,Gee, C.T.,Li, L.,Li, W.,Lee, R.E.,Rankovic, Z.,Chen, T.,Potts, P.R.
Structural basis for substrate recognition and chemical inhibition of oncogenic MAGE ubiquitin ligases.
Nat Commun, 11:4931-4931, 2020
Cited by
PubMed Abstract: Testis-restricted melanoma antigen (MAGE) proteins are frequently hijacked in cancer and play a critical role in tumorigenesis. MAGEs assemble with E3 ubiquitin ligases and function as substrate adaptors that direct the ubiquitination of novel targets, including key tumor suppressors. However, how MAGEs recognize their targets is unknown and has impeded the development of MAGE-directed therapeutics. Here, we report the structural basis for substrate recognition by MAGE ubiquitin ligases. Biochemical analysis of the degron motif recognized by MAGE-A11 and the crystal structure of MAGE-A11 bound to the PCF11 substrate uncovered a conserved substrate binding cleft (SBC) in MAGEs. Mutation of the SBC disrupted substrate recognition by MAGEs and blocked MAGE-A11 oncogenic activity. A chemical screen for inhibitors of MAGE-A11:substrate interaction identified 4-Aminoquinolines as potent inhibitors of MAGE-A11 that show selective cytotoxicity. These findings provide important insights into the large family of MAGE ubiquitin ligases and identify approaches for developing cancer-specific therapeutics.
PubMed: 33004795
DOI: 10.1038/s41467-020-18708-x
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.19 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon